Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Balanced Salt Solution (BSS) Solution Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

The Evaluation of Balanced Salt Solution During Cataract Surgery

NCT05853978
View directory record Official record
Conditions
Fuchs Dystrophy, Cataract
Interventions
BSS Plus, BSS
Drug
Lead sponsor
Adam Fedyk, MD, FACS
Other
Eligibility
22 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Town and Country, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

NCT02652780
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

NCT00853905
View directory record Official record
Conditions
Glaucoma
Interventions
Triesence, balanced salt solution BSS
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 4 Interventional Results available

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

NCT00798577
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Vigamox Ophthalmic Solution, BSS placebo
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2010 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

NCT02132312
View directory record Official record
Conditions
Unilateral Cataract Extraction, Congenital Cataract
Interventions
OMS302, Phenylephrine HCl
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
1 Day to 47 Months
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 1Phase 2 Interventional

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

NCT00721695
View directory record Official record
Conditions
Cataract Extraction
Interventions
OMS302, OMS302-PE, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Redding, California • Bloomington, Minnesota • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01579565
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

RESCUE and REVERSE Long-term Follow-up

NCT03406104
View directory record Official record
Conditions
Leber Hereditary Optic Neuropathy
Interventions
GS010, Sham Intravitreal Injection
Genetic · Other
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Pasadena, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

NCT01193127
View directory record Official record
Conditions
Cataract
Interventions
OMS302 Solution, OMS302 Mydriatic Solution, OMS302 Anti-inflammatory Solution, Balanced Salt Solution (BSS) Solution
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Chandler, Arizona • Glendale, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Sep 15, 2026, 11:26 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Studying the Relationship Between Contact Lens Packaging Solutions and Bacterial Binding to Surface Eye Cells

NCT01104961
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Contact lens packaging solution, Balanced salt solution (BSS)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 38 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 15, 2026, 11:26 AM EDT
Recruiting Phase 2 Interventional

Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye

NCT07413172
View directory record Official record
Conditions
Dry Eye, Eye Diseases, Eyes Dry Chronic
Interventions
Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate), Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS), Standard of Care (SOC) Treatment
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 15, 2026, 11:26 AM EDT
Recruiting Phase 4 Interventional

Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?

NCT05663684
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 3 Interventional

Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction

NCT00245271
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
17 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Redwood City, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 15, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ahmed Glaucoma Valve Surgery With Mitomycin-C

NCT02805257
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
Interventions
Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant
Drug · Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 15, 2026, 11:26 AM EDT
Terminated Phase 4 Interventional Results available

Does Topical Ophthalmic Anesthetic Prior to Probing and Irrigation Decrease Pain?

NCT04229771
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 15, 2026, 11:26 AM EDT